Adaptimmune Therapeutics plc (ADAP) DCF Valuation

Adaptimmune Therapeutics plc (ADAP) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Adaptimmune Therapeutics plc (ADAP) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore the financial potential of Adaptimmune Therapeutics plc (ADAP) with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate the intrinsic value of Adaptimmune and refine your investment strategy.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 1.1 4.0 6.1 27.1 60.3 113.8 215.0 405.9 766.6 1,447.6
Revenue Growth, % 0 252.76 55.36 341.5 122.05 88.84 88.84 88.84 88.84 88.84
EBITDA -131.8 -125.8 -155.7 -155.6 -128.2 -113.8 -215.0 -405.9 -766.6 -1,447.6
EBITDA, % -11743.32 -3178.65 -2531.78 -573.13 -212.67 -100 -100 -100 -100 -100
Depreciation 8.0 7.7 6.6 6.1 9.8 77.1 145.6 275.0 519.2 980.5
Depreciation, % 716.86 193.36 106.79 22.36 16.32 67.74 67.74 67.74 67.74 67.74
EBIT -139.8 -133.5 -162.2 -161.7 -138.0 -113.8 -215.0 -405.9 -766.6 -1,447.6
EBIT, % -12460.17 -3372.01 -2638.56 -595.49 -228.99 -100 -100 -100 -100 -100
Total Cash 89.5 368.2 369.6 204.6 146.9 113.8 215.0 405.9 766.6 1,447.6
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 19.3 .1 .8 7.4 46.9
Account Receivables, % 1718.72 3.51 12.23 27.39 77.83
Inventories 1.5 2.1 .7 1.3 .0 38.6 72.9 137.6 259.9 490.9
Inventories, % 130.04 52.7 12.13 4.71 0 33.91 33.91 33.91 33.91 33.91
Accounts Payable 6.4 6.4 8.1 4.8 8.1 75.4 142.3 268.7 507.5 958.3
Accounts Payable, % 566.58 161.42 131.94 17.51 13.48 66.2 66.2 66.2 66.2 66.2
Capital Expenditure -3.1 -2.9 -8.8 -29.7 -4.9 -86.9 -164.0 -309.7 -584.9 -1,104.5
Capital Expenditure, % -273.98 -73.42 -142.8 -109.55 -8.1 -76.3 -76.3 -76.3 -76.3 -76.3
Tax Rate, % -1.19 -1.19 -1.19 -1.19 -1.19 -1.19 -1.19 -1.19 -1.19 -1.19
EBITAT -140.1 -133.6 -163.1 -164.1 -139.7 -113.8 -215.0 -405.9 -766.6 -1,447.6
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -149.5 -110.3 -162.8 -198.4 -169.5 -98.3 -245.4 -463.4 -875.2 -1,652.6
WACC, % 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.2 13.2
PV UFCF
SUM PV UFCF -2,020.2
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -1,686
Terminal Value -15,057
Present Terminal Value -8,102
Enterprise Value -10,122
Net Debt -119
Equity Value -10,003
Diluted Shares Outstanding, MM 201
Equity Value Per Share -49.75

What You Will Get

  • Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Adaptimmune Therapeutics plc’s financial data pre-filled to kickstart your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
  • Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.

Key Features

  • Real-Life ADAP Data: Pre-filled with Adaptimmune Therapeutics' historical financials and future projections.
  • Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
  • Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your inputs.
  • Scenario Testing: Develop multiple forecasting scenarios to assess various valuation outcomes.
  • User-Friendly Design: Intuitive, organized, and crafted for both professionals and newcomers.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Adaptimmune data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Adaptimmune’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Adaptimmune Therapeutics plc (ADAP)?

  • Accuracy: Utilizes real Adaptimmune financial data for precise calculations.
  • Flexibility: Allows users to easily modify and test various inputs.
  • Time-Saving: Eliminates the need to create a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and precision expected by CFOs.
  • User-Friendly: Intuitive design makes it accessible for users without advanced financial skills.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Adaptimmune Therapeutics plc (ADAP) stock.
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models for Adaptimmune Therapeutics plc (ADAP).
  • Consultants: Deliver professional valuation insights on Adaptimmune Therapeutics plc (ADAP) to clients quickly and accurately.
  • Business Owners: Understand how biotechnology firms like Adaptimmune Therapeutics plc (ADAP) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to Adaptimmune Therapeutics plc (ADAP).

What the Template Contains

  • Historical Data: Includes Adaptimmune Therapeutics plc’s past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Adaptimmune Therapeutics plc’s intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Adaptimmune Therapeutics plc’s financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.